K
Kriya Therapeutics
Biotech & Life Sciences · Morrisville, United States · Founded 2019
Global footprint
Where Kriya Therapeutics has talent and traffic
team presence
across markets
Talent graph
The shape of Kriya Therapeutics's talent
Dealroom maps Kriya Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.
Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.
Patent intelligence
$415k patent portfolio · 11 active families
Where Kriya Therapeutics concentrates vs peers
Each axis is a top-10 topic across Kriya Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Capital deployed
Kriya Therapeutics's 3 investments and acquisitions.
Every disclosed deal where Kriya Therapeutics appeared as a backer or acquirer, 2022–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across Kriya Therapeutics's capital deployment.
Where the deals concentrate by sector, stage, and decade.
01 · Deployment strategy vs peers
Where Kriya Therapeutics deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
02 · Portfolio market map
Kriya Therapeutics's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
What the market is saying about Kriya Therapeutics
An AI-synthesized read of the highest-engagement posts about Kriya Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kriya Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.